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Nonstimulatory peptide–MHC enhances human T-
cell antigen-speciﬁc responses by amplifying
proximal TCR signaling
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Foreign antigens are presented by antigen-presenting cells in the presence of abundant
endogenous peptides that are nonstimulatory to the T cell. In mouse T cells, endogenous,
nonstimulatory peptides have been shown to enhance responses to speciﬁc peptide antigens,
a phenomenon termed coagonism. However, whether coagonism also occurs in human
T cells is unclear, and the molecular mechanism of coagonism is still under debate since CD4
and CD8 coagonism requires different interactions. Here we show that the nonstimulatory,
HIV-derived peptide GAG enhances a speciﬁc human cytotoxic T lymphocyte response to
HBV-derived epitopes presented by HLA-A*02:01. Coagonism in human T cells requires the
CD8 coreceptor, but not T-cell receptor (TCR) binding to the nonstimulatory peptide–MHC.
Coagonists enhance the phosphorylation and recruitment of several molecules involved in the
TCR-proximal signaling pathway, suggesting that coagonists promote T-cell responses to
antigenic pMHC by amplifying TCR-proximal signaling.
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During the activation of T cells, a small number of foreignantigenic peptides bound to MHC proteins (pMHC) aretypically presented in the midst of a vast majority of
pMHC-presenting peptides derived from endogenous proteins.
T-cell receptor (TCR) binds to pMHC complex with an afﬁnity
dependent on the peptide sequence that is presented, whereas the
CD8 or CD4 coreceptors can bind to pMHC with afﬁnities
independent of the peptide sequence. A T cell needs to identify
the limited number of its speciﬁc antigenic pMHC among the
excess of self pMHC. T cells are very sensitive to antigenic pMHC
and can be activated by a single-antigenic pMHC1, yet, at the
same time they require cross-linking of TCRs in order to be
stimulated2. Understanding how T cells identify and differentiate
the small pool of antigenic pMHC molecules from the endo-
genous pMHC molecules, and the role of endogenous pMHC
during the T-cell response to speciﬁc antigenic pMHC can pro-
vide critical insights into early molecular events during T-cell
activation. Several studies demonstrated that simultaneous pre-
sentation of nonstimulatory pMHC in the presence of antigenic
pMHC can signiﬁcantly enhance mouse T-cell responses to
antigenic pMHC3–5. This phenomenon is termed coagonism2,6,7.
A heterodimer of antigenic pMHC with certain nonstimulatory
pMHC, but not monomers of antigenic pMHC, can enhance
mouse CD4+ T-cell responses3. However, it was unclear why this
coagonist activity did not work for all kinds of nonstimulatory
pMHC molecules. Coagonism has also been demonstrated in
mouse OT-I CD8+ T cells, but it had no requirements for speciﬁc
sequences of the coagonist peptides4,5. Hence, there is clear evi-
dence for a role for the large excess of endogenous non-
stimulatory pMHC complexes in antigen-speciﬁc mouse T-cell
activation; however, the molecular mechanism underlying this
effect is unknown
The molecular interactions required for coagonism initially
appeared to differ between MHC class I (MHCI)-restricted CD8+
T cells and MHC class II (MHCII)-restricted CD4+ T cells. The
fact that not all of the tested nonstimulatory peptides could
induce coagonism in CD4+ T cells3, while they could in OT-I
CD8+ T cells4,5 was a conundrum. These apparent differences
were resolved by demonstrating that the requirement for speciﬁc
peptides as coagonists depends on the particular TCR system,
primarily on the strength of the coreceptor interaction with the
pMHC8. While binding of CD4 to nonstimulatory pMHCII was
not necessary for the coagonism to be effective3, binding of CD8
to nonstimulatory pMHCI was absolutely essential for coagon-
ism8. If this interaction was strong (e.g., with H2-Kb, as in the
OT-I TCR system), then there was no measurable requirement
for the TCR to recognize the self-peptide in the coagonist MHC
molecule. On the other hand, if the CD8 interaction with the
coagonist was weaker (e.g., with H2-Db, recognized by F5 TCR),
then the TCR required the interaction with the coagonist and
could distinguish between different nonstimulatory coagonist
pMHC8. The weak interaction between CD4 and MHCII9,
therefore explains the peptide speciﬁcity of coagonism in CD4+
T cells3. Human CD8–MHCI interactions extend over a wide
range of binding afﬁnities and are mostly weaker than those
between mouse CD8 and H2-Kb10, suggesting that the molecular
requirements for coagonism during human T-cell recognition
may differ from those in murine T cells. Critically, it is not known
how the presence of coagonist pMHC complexes inﬂuences
downstream TCR signaling pathways. Furthermore, previous
research has mostly focused on mouse T-cell responses with
limited examination of coagonism during human T-cell
activation.
Coagonism has important implications for human immune
responses. Expression of cell surface HLA-C was shown to be
associated with the cytotoxic response to HIV infection; high
HLA-C expression was also shown to increase the risk of Crohn’s
disease11. In many viral infections, viruses downregulate cell
surface MHC molecules using various strategies12. Moreover,
several solid and hematopoietic tumors downregulate MHC
expression13. However, it is not known if this reduction in total
MHC affects human T-cell responses due to a reduction in
antigenic pMHC amount or to a coagonist-mediated mechanism.
Very little is currently known about coagonism during human
T-cell activation, primarily due to the genetic and experimental
constraints of working with human systems. In order to work
with an antigen-speciﬁc TCR, only well-described cytotoxic T
lymphocyte (CTL) clones are readily available. There is some
evidence for coagonism in human CD8+ T-cell activation, as
nonstimulatory pMHC were found to provide a cooperative
contribution to the human CTL response to antigenic pMHC
presented on carrier quantum dots14. However, this study was
based on an artiﬁcial and nonphysiological antigen-presenting
system instead of investigating direct interactions between
antigen-presenting cells (APCs) and human T cells. Moreover,
the molecular interactions and the mechanism of coagonism
during human T-cell activation are currently unknown. To ﬁll in
this gap, we decided to use a cell-based antigen presentation
system to present antigenic and nonstimulatory pMHC to sti-
mulate human CTL clones speciﬁc for an epitope of the Hepatitis
B virus (HBV).
Here, we ﬁnd that nonstimulatory peptides enhance HBV
antigen-speciﬁc human CD8+ T-cell responses to small amounts
of HBV-derived antigen. CD8 binding, but not TCR binding, to
the nonstimulatory pMHCI is required for coagonism to help T-
cell activation. Nonstimulatory pMHCI also enhances the T-cell
response when CD8 binding to the MHCI molecule presenting
the antigenic peptide is abrogated. Mechanistically, coagonist
pMHC enhances the phosphorylation of CD3ζ, Zap70, LAT,
PLC-γ1, and Erk, and recruits more phosphorylated CD3ζ,
phosphorylated Lck, and phosphorylated Zap70 into the immu-
nological synapse, demonstrating that coagonist pMHC ampliﬁes
proximal TCR signaling strength during recognition of a limited
amount of antigen. Unexpectedly, this coagonsim-induced
increase in CD3ζ phosphorylation is not accompanied by an
enhanced TCR/CD3 complex cell surface downregulation, sug-
gesting that coagonism does not increase the number of triggered
TCR molecules (bystander activation), but acts to amplify signal
from TCRs engaged by agonist pMHC. This study conﬁrms a role
for coagonism in human CD8+ T-cell activation using physio-
logical antigen-presenting cells, and shows that coagonism acts at
the level of the TCR-proximal signaling pathway. It also
demonstrates that the coreceptor can work by binding to a dif-
ferent pMHC molecule than the one presenting antigen to the
TCR.
Results
T-REx CHO cells expressing single-chain pMHC trimer as
APC. We previously used the mouse Tap2-deﬁcient cell line
RMA-S as an APC for mouse coagonist studies4,5,8. A human
Tap2-deﬁcient cell line, T2, was therefore tested as an APC for
human coagonist studies. However, we found that T2 cells
already express a relatively high amount of HLA-A*02:01 (HLA-
A2) on the surface, and that pulsing with peptides did not sig-
niﬁcantly upregulate the surface amount of HLA-A2 (Supple-
mentary Fig. 1). HLA-A2 on T2 cells present signal sequence-
derived peptides, which may explain this result15, leading us to
look for another model system. In order to express human
peptide–MHC complexes in a xenogenic cell line (no human
MHC expression), a tetracycline-regulated expression (T-REx)
CHO cell line was used8. T-REx cells express the tet repressor
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under blasticidin selection. We transfected T-REx cells with
recombinant vectors for human single-chain peptide–MHCI
complex (sc pMHCI). Such single-chain trimers express pMHCI
as a polypeptide by linking the peptide, β2-microglobulin and
MHC heavy chain with ﬂexible linkers8,16,17. A tetracycline-
inducible vector pcDNA5/TO was used to express the HIV GAG
peptide (SLYNTVATL) or two different HBV-derived peptides,
E183-91(FLLTRILTI: “E183”) and C18-27 (FLPSDFFPSV:
“C18”), as a sc trimer of A2 in T-REx cells. Without doxycycline,
the transfected T-REx cells express small amounts of “leaky” (low
amount) sc pMHCI. Strong expression of (high amount) sc
pMHCI is induced by adding 50 ng ml−1 doxycycline. The
expression of cell surface HLA-A2 was detected by anti-HLA-A2
antibody staining (Fig. 1a). “TCR-like” antibodies that recognize
HLA-A2 in association with the HBV peptides18 described above
were used to quantitate the expression of the speciﬁc epitopes.
Anti-C18-A2 or anti-E183-A2 antibodies showed similar
expression proﬁles conﬁrming the correct peptide–MHC
expression (Fig. 1b). However, some cross-recognition was also
observed with the TCR-like antibodies, wherein high amount of
E183-HLA-A2 could be partially recognized by anti-C18-A2
antibody, and high amount of C18-HLA-A2 could be partially
recognized by anti-E183-A2 (Fig. 1c).
In order to conﬁrm that HLA in the single-chain format can be
recognized by the cognate TCR, a human CTL line bearing TCR
speciﬁc for E183-HLA-A2 complex18 was cocultured with the stably
transfected T-REx cell panel for 3 h, and the expression of the
cytokines TNF and IFN-γ, and the degranulation marker CD107a
were detected. The data showed that sc pMHCI induced CD8+ T-
cell effector functions in an antigen-speciﬁc manner (Fig. 1d).
Nonstimulatory pMHC enhance human CTL response to
antigen. To investigate coagonism in human E183 CTL, we
cloned sc GAG-HLA-A2 into the constitutive expression vector
pcDNA3-Clover, which was supertransfected into a T-REx clone
that could simultaneously express low amount of sc E183-HLA-
A2. Single cell sorting was performed after supertransfection and
antibiotic selection. Total surface expression of HLA-A2 was
measured by staining with anti-HLA-A2 (Fig. 2a). The amount of
E183-HLA-A2 under repressed conditions was the same in the
presence or absence of supertransfected GAG-HLA-A2 as
determined using E183-A2 antibody staining (Fig. 2b). In order to
test if coagonism occurs during human T-cell activation, the
panel of T-REx clones was cocultured with human E183-speciﬁc
CTL for 3 h, following which, cell surface expression of the
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Fig. 1 Inducible expression of human single-chain (sc)-MHCI in T-REx CHO cells and their immunogenicity to human CTL. a anti-HLA-A2 staining of T-REx
CHO clones expressing low amount or high amounts of (doxycycline-induced) human single-chain (sc)-MHCI. b TCR-like antibody anti-C18-HLA-A2 or
anti-E183-HLA-A2 staining of T-REx CHO clones expressing low or high concentrations of C18/E183-HLA-A2 sc pMHC. c TCR-like antibody anti-C18-HLA-
A2 or anti-E183-HLA-A2 staining of T-REx CHO clones expressing low or high C18/E183-HLA-A2 sc pMHC, high concentration of GAG-HLA-A2 sc pMHC,
and unstransfected T-REx CHO cells. d Human E183 epitope-speciﬁc CTL were cultured with the indicated T-REx CHO cells for 3 h and cytokine expression
(TNF and IFN-γ) and upregulation of the degranulation marker CD107a were assessed by ﬂow cytometry. Data are representative of ﬁve independent
experiments
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degranulation marker CD107a, and intracellular expression of
cytokines TNF and IFN-γ were analyzed by ﬂow cytometry. The
data show that the simultaneous expression of sc GAG-HLA-A2
signiﬁcantly enhanced the anti-E183 CTL functional responses
(Fig. 2c). The same T-REx panel was also cultured with the anti-
E183 CTL for 24 h and an IL-2 ELISA was performed. The result
showed that high expression of sc GAG-HLA-A2 also enhanced
IL-2 secretion (Fig. 2d). In order to conﬁrm coagonism in a
different human T-cell system, similar experiments were also
performed in TCR-transduced (TCR-Td) human T cells expres-
sing C18-speciﬁc TCR or E183-speciﬁc TCR19. After 3 h stimu-
lation by the respective T-REx CHO cells panel, nonstimulatory
sc E183-HLA-A2 or sc GAG-HLA-A2 enhanced C18-speciﬁc-
TCR-Td T-cell activation in response to antigen sc C18-HLA-A2,
and nonstimulatory sc C18-HLA-A2, and sc GAG-HLA-A2
enhanced E183-speciﬁc TCR-Td T-cell activation in response to
antigen sc E183-HLA-A2 (Supplementary Fig. 2). Therefore, our
data show for the ﬁrst time that the nonstimulatory pMHC can
aid in the response of human T cells to antigenic pMHC in the
context of physiological interactions between T cell and antigen-
presenting cell.
CD8 binding to coagonist pMHC is required for coagonism. In
the murine immune system, CD8 binding to the coagonist pMHC
is required for coagonism. There are several well-studied muta-
tions on HLA-A that can alter the binding afﬁnity of CD8 for
HLA class I. The D227K, T228A double mutation abrogates CD8
binding;20 the A245V mutation reduces CD8-binding afﬁnity
fourfold;21 whereas the Q115E mutation enhances CD8-binding
afﬁnity 1.5-fold22. First, we tested if these mutations could alter
the CD8 binding by introducing the mutation into sc E183-HLA-
A2 in pcDNA5/TO vectors. Functional activation data showed
that the D227K, T228A mutation on the agonist pMHC complex
can effectively abrogate T-cell activation and that the A245V
mutation reduced IFN-γ production by 25% (Fig. 3a). To test the
requirement of CD8 binding to the coagonist pMHC for coa-
gonism activation enhancement, the three mutations were sepa-
rately introduced into sc GAG-HLA-A2 (sc GAG-HLA-A2-
CD8mut) in pcDNA3-Clover and were then supertransfected into
T-REx cells expressing tet-inducible sc E183-HLA-A2. Total
HLA-A2 and antigen E183-HLA-A2 expression were assessed by
ﬂow cytometry (Fig. 3b, c). These cells were then cocultured with
the anti-E183 CTL for 3 h and cytokine production was
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Fig. 2 Nonstimulatory pMHCI can enhance human CTL response to antigen. a Anti-HLA-A2 staining of T-REx CHO clones used in the coagonism
experiments. b Measurement of the amount of the antigen, E183-HLA-A2 in T-REx CHO clones by staining with TCR-like antibody anti-E183-HLA-A2.
c Human E183 CTL were cultured with the indicated T-REx CHO clones panel for 3 h and cytokine expression (TNF and IFN-γ) and upregulation of the
degranulation marker CD107a were assessed by ﬂow cytometry. d Human E183 CTL were cultured with the indicated T-REx CHO clones panel for 24 h,
and the amount of IL-2 in the supernatant was assessed by ELISA. Statistical signiﬁcance was determined by using unpaired two-sided Student’s t test and
shown as mean ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001). Data are representative of ﬁve independent experiments. MFI mean ﬂuorescence level
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determined. Compared to wild type HLA-A2 coagonist, the
CD8mut variants (D227K, T228A, and A245V) of sc GAG-HLA-
A2 could not enhance the anti-E183 CTL response (Fig. 3d).
Therefore, CD8 binding to coagonist is required for coagonism in
human T-cell activation. The enhanced binding CD8mut-Q115E
variant of sc GAG-HLA-A2, however, could not further enhance
the coagonism.
TCR binding to coagonist is not required for coagonism. TCR
recognition of the coagonist pMHC was shown to be important in
coagonist enhancement of CD4+ T-cell activation and for the F5
CD8+ T-cell activation3,8. However, in OT-I CD8+ T cells several
nonstimulatory pMHC could act as coagonists, demonstrating
that the OT-I TCR does not discriminate between coagonist
pMHC complexes4,5,8. In order to investigate the requirement for
TCR recognition of coagonist in human T-cell coagonism, we
introduced the K66A mutation into sc E183-HLA-A2 in
pcDNA5TO (Supplementary Fig. 3A). This mutation was pre-
viously shown to abrogate TCR recognition in a wide range of
TCRs restricted by HLA-A2 (Tax11–19 and M158–66 peptide)23–25,
but it did not totally abrogate E183 CTL TCR recognition of sc
E183-HLA-A2-K66A (Supplementary Fig. 3B). We also intro-
duced the K66A mutation into sc GAG-HLA-A2 in pcDNA3-
Clover. The supertransfection of sc GAG-HLA-A2-K66A into the
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Fig. 3 CD8 binding to nonstimulatory pMHCI is required for coagonism in human T cells. a D227K, T228A, or A245V mutations were introduced in the
antigen sc E183-HLA-A2 (sc E183-HLA-A2-CD8mut). Doxycycline-inducible sc E183-HLA-A2-CD8mut constructs were transfected into T-REx CHO cells.
Single cell clones were used to stimulate human E183 CTL for 3 h. Cytokine production (TNF and IFN-γ) and upregulation of the degranulation marker
CD107a in E183 CTL were assessed by ﬂow cytometry. b D227K, T228A, A245V, or Q115E mutations were introduced in the nonstimulatory sc GAG-HLA-
A2 (sc GAG-HLA-A2-CD8mut). sc GAG-HLA-A2-CD8mut constructs were transfected into the T-REx CHO clone that could simultaneously express low
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production (TNF and IFN-γ) and upregulation of the degranulation marker CD107a were assessed by ﬂow cytometry. Statistical signiﬁcance was
determined by using unpaired two-sided Student’s t test and shown as mean ± s.d. (ns nonsigniﬁcant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Data are representative of three independent experiments. MFI mean ﬂuorescence level
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clone expressing tet-inducible E183-HLA-A2 showed that
expression of sc GAG-HLA-A2-K66A was lower than the non-
mutant HLA-A2 (Supplementary Fig. 3C). We inferred that the
K66A mutation affects peptide binding to the MHC grove and
makes the pMHC complex unstable. We also tested the E166K
mutation that was used in the mouse coagonism study8 (Sup-
plementary Fig. 3A). Similar to K66A, the E166K mutation could
not abrogate TCR recognition in E183 CTL (Supplementary
Fig. 3B). Based on previous research26, we then tested alternative
mutation sites such as R65A, V152E, E154K, Q155K, L156F, and
E161V by introducing these mutations into sc E183-HLA-A2 and
stimulating anti-E183 CTL using transiently transfected T-REx
cells. Of these mutants, only V152E completely abrogated TCR
recognition (Supplementary Fig. 4A, B). After selecting and
cloning T-REx cells expressing the V152E mutant of sc E183-
HLA-A2, we conﬁrmed that V152E abrogated TCR recognition
of E183 (Fig. 4a). We also introduced the V152E mutation into
GAG-HLA-A2, and demonstrated that this also abrogated GAG-
A2-speciﬁc TCR-transduced T-cell27 recognition of the GAG-A2
complex (Supplementary Fig. 5). We then supertransfected sc
GAG-HLA-A2 into the clone expressing inducible sc E183-HLA-
A2. After antibiotic selection and single cell sorting, we evaluated
coagonism. The total HLA-A2 and antigen sc E183-HLA-A2
expression were measured by antibody staining and ﬂow cyto-
metry, showing that the clones expressed similar amounts of
HLA-A2 (Fig. 4b) and antigen E183-A2 (Fig. 4c). In coagonism
experiments, the sc GAG-HLA-A2-V152E was still able to
enhance T-cell activation to repressed E183-HLA-A2 (Fig. 4d).
Therefore, TCR binding to the coagonist ligands is not required
for coagonism during activation in E183 CTL line.
CD8 binding to coagonist is sufﬁcient to activate T cells. The
classical model of T-cell activation typically shows the TCR and
coreceptor binding to the same antigenic pMHC and initiating
TCR signaling (see Fig. 11 of Chapter 7 of Ref. 28)2,28. Hoerter
et al.8 showed that TCR binding to nonstimulatory pMHC is
required for coagonism when the CD8 binding to antigenic
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pMHC is abrogated. To evaluate the need for CD8 binding to
antigenic pMHC in human T-cell activation, we introduced the
D227K, T228A, or A245V mutations in sc E183-HLA-A2. When
only these mutant HLA-A2 molecules were expressed on the
surface of T-REx cells, D227K, T228A completely abolished T-cell
activation, while A245V strongly reduced activation (Fig. 3a), as
expected. However, simultaneous expression of sc GAG-HLA-A2
could signiﬁcantly rescue and enhance T-cell activation (Fig. 5a,
b). This demonstrates that CD8 binding only to nonstimulatory
(coagonist) pMHC molecules is sufﬁcient to initiate T-cell sig-
naling when the TCR is able to interact with antigenic pMHC.
Therefore, T-cell activation does not require CD8 and TCR to
bind to the same antigenic pMHC. Thus, nonstimulatory pMHC
plays an important role in initiating and amplifying T-cell
activation.
Lack of CD8 and CD3 downregulation by coagonism. T-cell
activation usually induces downregulation of cell surface CD8 and
TCR/CD329. We, therefore, tested if the downregulation of cell
surface CD8 and CD3 is further increased during coagonism-
mediated T-cell activation enhancement. Our data show that the
nonstimulatory pMHC did not signiﬁcantly induce more down-
regulation of cell surface CD3 or CD8 compared to low amount
antigenic pMHC alone, whereas high expression of antigen
strongly downregulated cell surface CD8 and CD3 (Fig. 6). This
suggests that coagonism does not amplify T-cell activation by
triggering, and subsequent endocytosis of, bystander TCR.
Coagonist pMHC amplify the proximal TCR signaling
strength. The pseudodimer or the preconcentration models of
coagonism suggest that the nonstimulatory pMHC can recruit
more Lck-associated coreceptor to the immunological
synapse2,3,6. In order to test if TCR-proximal signaling pathways
play an important role in coagonism, we analyzed phosphoryla-
tion of molecules downstream of TCR signaling30. Firstly, we
tested if coagonism could enhance the amount of active Lck (p-
Y394 Lck). We found that the amount of active Lck was relatively
stable even in the absence of TCR stimulation (Supplementary
Figs. 6, 8), in accordance with previous reports31. We then tested
if phosphorylation of CD3ζ, presumably by active Lck, was
increased due to the presence of coagonist pMHC. Compared to
the low amount of antigen alone, the coagonists signiﬁcantly
enhanced the phosphorylation of CD3ζ (Fig. 7a, Supplementary
Fig. 8). Similarly, coagonist pMHC ampliﬁed phosphorylation of
Zap70, LAT, PLC-γ1, Erk, and phosphatase SHP-1, suggesting
that proximal TCR signaling is enhanced in the presence of
coagonist pMHC (Fig. 7b–f, Supplementary Fig. 8).
In order to investigate proximal TCR signaling at the
immunological synapse, we analyzed the recruitment of mole-
cules to the synapse by total internal reﬂection ﬂuorescence
microscopy (TIRF). Supported lipid bilayers were used to present
pMHC monomers to stimulate human T cells. Phosphorylated
CD3ζ, active Lck, and pZap70 were visualized by antibody
staining and TIRF imaging. In the negative control (“No
pMHC”), proper formation of synapse was not seen. Therefore,
the mean intensity of ﬂuorescence could not be quantiﬁed for the
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“No pMHC” control. Compared to low concentration of
antigenic E183-A2 monomer (10 nM), the simultaneous pre-
sentation of high concentration (1 μM) of nonstimulatory GAG-
A2 monomer with 10 nM E183-A2 signiﬁcantly enhanced
recruitment of pCD3ζ into the immunological synapse. In
contrast, 1 μM GAG-A2 monomer alone recruited very little
pCD3ζ into the immunological synapse (Fig. 8a, b). For active
Lck, the coagonist GAG-A2 monomer could slightly, but
signiﬁcantly enhance the recruitment of active Lck into the
immunological synapse compared to low concentration of
antigen alone (Fig. 8c, d). For high concentrations of GAG-A2
monomer alone, synapse formation and recruitment of active Lck
to the synapse were seen; this might be because pLck is
constitutively present at the cell membrane and can be detected
in the TIRF mode (Fig. 8c, d). For pZap70, the coagonist GAG-
A2 monomer together with low concentration of antigen
signiﬁcantly enhanced the recruitment of pZap70 into the
synapse (Fig. 8e, f). For high concentration of nonstimulatory
GAG-A2 monomer alone, there was recruitment of a small
amount of pZap70 in the immunological synapse, suggesting that
nonstimulatory pMHC alone can induce recruitment of Zap70
(Fig. 8e, f). To study if synapse formation by nonstimulatory
GAG-A2 monomer requires intact CD8 binding to the GAG-A2
monomer, D227K/T228A mutation was introduced into the
monomer. TIRF imaging results of both pLck and
pZap70 showed that the GAG-A2-CD8mut monomer could not
form the immunological synapse, establishing that intact CD8
binding to pMHC is required to form the immunological synapse
(Supplementary Fig. 7).
Discussion
Nonstimulatory pMHC complexes have been shown to enhance
mouse antigen-speciﬁc T-cell responses in multiple experimental
systems3–5,8,32–35, but the molecular mechanism of this phe-
nomenon of coagonism and its relevance to human T-cell
responses are poorly understood. We used a human CTL line
speciﬁc for an HBV-derived peptide and expressed the antigenic
pMHC as a single-chain trimer (sc E183-HLA-A2). The HIV-
derived peptide GAG was also expressed as a single-chain trimer
in order to study coagonism, because it is nonstimulatory for this
CTL. We found that sc GAG-HLA-A2 could enhance antigen
recognition by the E183-speciﬁc CTL, improving effector func-
tions such as the production of cytokines IL-2, TNF, and IFN-γ.
This ﬁnding is the ﬁrst demonstration of coagonism in human
T cells responding to antigen presented on APCs. We then used
this experimental system to map out the molecular interactions
required for coagonism in human CD8+ T cells and to investigate
TCR signaling pathways induced by coagonist pMHC
recognition.
To enable the study of the molecular interactions required for
coagonism in human T-cell activation, different mutations that
could abrogate CD8 or TCR binding to MHC were introduced
into the coagonist MHC molecules. We found that coagonism in
human E183 CTL required CD8 binding to the nonstimulatory
pMHC. Interestingly, TCR recognition of the nonstimulatory
pMHC was not required. In mouse CD4+ T cells, effective coa-
gonism requires TCR binding to coagonist pMHC since only a
small proportion of the nonstimulatory peptides tested could
work as coagonists3. However, in mouse CD8+ T cells coagonism
usually requires CD8 binding to coagonist pMHC, while the
TCR-coagonist binding depends on the afﬁnity of CD8 binding to
coagonist pMHC4,5,8. Since the afﬁnity of human CD8 binding to
HLA is usually lower than that of murine CD8 to H-2 molecules,
we had predicted that coagonism in human CD8 T cells would
require some degree of TCR binding to the nonstimulatory
pMHC complex8. However, our current study has revealed that at
least in human E183-HLA-A2-restricted CTL, coagonism does
not require TCR binding to the coagonist nonstimulatory pMHC.
The molecular mechanism underlying pMHC coagonism is a
subject of active study though it is still not known how the pre-
sence of nonstimulatory pMHC complexes can amplify the
antigen-speciﬁc activation of T cells. Li et al.36 suggest that in
CD4+ T cells, CD4 controls the spatial localization of Lck. Upon
TCR engagement with antigenic pMHC, CD4 can recruit more
endogenous pMHC and trigger the TCR engaged with endo-
genous pMHC. Krogsgaard et al.3,6 proposed a pseudodimer
pMHC model in CD4+ T cells. In this model, CD4 acts as a
bridge to connect one antigenic pMHC with one nonstimulatory
pMHC to recruit more nonstimulatory pMHC into the synapse.
In murine CD8+ T cells, Yachi et al.4 found that nonstimulatory
pMHC alone was able to recruit the coreceptor into the immu-
nological synapse. We suggested a “preconcentration” model in
which the nonstimulatory pMHC can enhance the interaction
between coreceptor and TCR, resulting in enhanced recruitment
of pMHC and coreceptor-Lck into the immunological synapse to
accelerate the scanning of different peptides2. However, the role
of coagonist pMHC recognition in the modulation of down-
stream signaling pathways is unknown. Critically, it is not known
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if the presence of coagonist pMHC complexes can enhance CD3
ITAM phosphorylation, and whether such an increase is due to
an increased phosphorylation of TCR/CD3 complexes bound to
antigenic pMHC, or due to an increased phosphorylation of
“bystander” TCR/CD3 complexes not engaged by antigenic
pMHC. We, therefore, investigated the effect of coagonist pMHC
on TCR signaling pathways. We found that coagonists enhanced
the phosphorylation of CD3ζ, Zap70, LAT, PLC-γ1, and Erk,
suggesting that the TCR signaling strength was ampliﬁed by the
coagonist. The total amount of active (phosphorylated Y394) Lck
was not affected by different conditions of stimulation, consistent
with previous reports31. We took advantage of TIRF microscopy
to study the role of coagonist pMHC complexes in the recruit-
ment of signaling molecules to the immunological synapse.
Unlike total active Lck amount detected in the western blotting
experiments, the amount of active Lck recruited into immuno-
logical synapse was enhanced by the coagonist. pCD3ζ and
pZap70 amount were also signiﬁcantly more enriched in the
immunological synapse in the presence of the coagonist.
High concentrations of antigen induced T-cell activation as
well as downregulation of TCR and CD8. However, high con-
centrations of nonstimulatory pMHC could enhance T-cell
functional responses to low concentration of antigen, but this
did not increase TCR or CD8 downregulation. This shows that
the endocytosis of TCR and CD8 is antigen dose-dependent and
is not affected by coagonism. Previous work showed that in a dual
TCR system, speciﬁc pMHC induced the downregulation of
engaged TCR rather than non-engaged TCR37. During coagon-
ism, the downregulated TCR are still agonist-engaged, and coa-
gonism may not trigger more bystander TCR to be
downregulated. From the western blotting data of pCD3ζ, we
found that the phosphorylation of CD3ζ was increased in coa-
gonism but to a lesser extent than during activation by a high
concentration of antigen. Previous studies also suggest that the
phosphorylation of ITAMs is required for TCR down-
regulation38,39. Therefore, the bystander TCR in coagonism may
not be phosphorylated, and is therefore not endocytosed.
Otherwise, we would expect to see more phosphorylation of CD3ζ
and further TCR downregulation. This could indicate differences
in signaling pathways in coagonist-aided activation compared to
high concentration antigen-induced activation, with coagonism-
induced activation enhancement leading to increase in phos-
phorylation of TCR/CD3 complexes engaged by the agonist TCR,
rather than increase in the number of phosphorylated TCR/CD3
complexes.
In conclusion, we propose an analog ampliﬁer model for the
mechanism of coagonism in human CD8+ T cells. The require-
ment of CD8 binding to nonstimulatory pMHC in coagonism
and the enhanced recruitment of Lck into the immunological
synapse suggest a CD8-Lck enrichment into the immunological
synapse driven by nonstimulatory pMHC. The increased phos-
phorylation of CD3ζ, but not of TCR downregulation indicates
that only TCRs engaged with agonist were further phosphory-
lated. Coagonism in human E183 CTL does not require TCR
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binding to nonstimulatory pMHC, further supporting our
hypothesis that bystander TCR may not be triggered in coagon-
ism. Therefore, coagonism likely works by further phosphor-
ylating each antigen-engaged TCR-CD3. For each antigen-
engaged T cell, the activation is further enhanced (analog)
rather than an all-or-nothing mode (digital). Therefore, we pro-
pose that coagonism works in an analog manner by further
enhancing the activation of each antigen-engaged T cell. The
enhanced phosphorylation of CD3ζ leads to the ampliﬁcation of
downstream signal strength, including the enhanced phosphor-
ylation of Zap70, LAT, PLC-γ1, and Erk. Therefore, coagonism is
an ampliﬁer of the entire TCR signaling pathway. The proposed
analog ampliﬁer model (Fig. 9) explains how the TCR signaling is
initiated and ampliﬁed under physiological conditions of APCs
presenting limited number of antigens together with large
amounts of endogenous nonstimulatory peptide–MHC.
Methods
Plasmids. Single-chain trimer GAG-HLA-A2 was a gift from Dr. Keith Gould
(Imperial College London). Peptide mutagenesis: GAG (SLYNTVATL) to E183-91
(FLLTRILTI) or C18-27 (FLPSDFFPSV); D227K-T228A, A245V and Q115E CD8-
binding mutations; K66A, R65A, E166K, V152E, E154K, Q155K, L156F, and
E161V TCR-binding mutations were all done by using QuickChange Site-Directed
Mutagenesis Kit (Stratagene). Agonist single-chain trimer was cloned into
tetracycline-inducible pcDNA5/TO (hygromycin resistance, Invitrogen). Non-
stimulatory single-chain trimer was cloned into pcDNA3-Clover (geneticin resis-
tance, a gift from Michael Lin [Addgene plasmid # 40259]).
Antibodies. Antibodies against HLA-A2 (BB7.2), HLA-ABC (W6/32), CD8a
(RPA-T8), TNF (MAb11), and IFN-γ (4 S.B3) were purchased from eBioscience.
Anti-CD3 (SK7), CD107a (H4A3), CD247-Alexa Fluor 488 (pY142) (K25-407.69),
pCD3ζ (pY142) (K25-407.69), Erk1 (Cat# 610031), and PLC-γ1 (Cat# 610027)
were from Becton Dickinson. Anti-pLAT (Tyr191) (Cat# 3584S), P-p44/42 MAPK
(T202/Y204) (Cat# 4370L), pSrc family (pY416) (Cat# 6943T), non-pSrc family
(pY416) (Cat# 2102S), pSHP-1 (Cat# 8849S), pZap70 (pY319) (Cat# 2717S), Zap70
(Cat# 2709), pPLC-γ1 (pY783) (Cat# 2821S), α-tubulin (Cat# 3873S), GAPDH
(Cat# 2118S) antibodies were from Cell Signaling Technologies. Anti-LAT (11B.12)
and β-2-microglobulin (2M2) antibodies were from Biolegend. Mouse anti-human
HLA-A2-E183-91 and mouse antihuman HLA-A2-C18-27 primary antibodies
were produced as described18. F(ab’)2-goat anti-rabbit IgG (H+ L) cross-adsorbed
secondary antibody, Alexa Fluor 488 (Cat# A-11070), and goat anti-mouse IgG (H
+ L) cross-adsorbed secondary antibody, Alexa Fluor 647 (Cat# A-21237) were
purchased from Thermo Fisher Scientiﬁc.
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T2-cell assay. T2 cells were obtained from ATCC. The cells have not been
authenticated and not been tested for mycoplasma. The cells were cultured with
RPMI-1640 media (Hyclone) supplemented with 10% fetal bovine serum (Hyclone),
2 mM L-glutamine (Gibco), 100 units ml−1 penicillin (Gibco), 100 μg ml−1 strep-
tomycin (Gibco) and MEM non-essential amino acid (Gibco). 106 T2 cells resus-
pend in 1ml media were pulsed with 1 μM E183 peptide (FLLTRILTI) dissolved in
DMSO at 37°C for 1 h. Cells were washed with media to remove extra peptide and
stained with anti-HLA-A2 antibody. The MFI of total HLA-A2 were analyzed on
ﬂow cytometry.
CHO cell culture and cloning. Tetracycline-Regulated Expression (T-REx) CHO
cell line was purchased from Invitrogen. The T-REx CHO cells have not been
authenticated and not been tested for mycoplasma. The CHO cells were cultured in
Ham’s F-12 (Gibco) medium with 10% fetal bovine serum (Hyclone), 2 mM L-
glutamine (Gibco), 100 units ml−1 penicillin (Gibco), 100 μg ml−1 streptomycin
(Gibco) and 10 μg ml−1 blasticidin S HCl (Invitrogen). The blasticidin was used for
maintaining the expression of the tetracycline repressor. Transfection of CHO was
done by using the polyethylenimine method. After transfection, the cells were
selected by the addition of drugs (0.3 mgml−1 hygromycin B from Invitrogen or
1.0 mg ml−1 G418 sulfate from Hyclone). High amount agonist expression was
induced by adding 60 ng ml−1 doxycycline. One day before the human CTL
activation assay, 2 × 104 CHO cells were seeded per well in a 96-well U bottom
plate. In all, 2 × 105 CHO cells were also seeded per well in a 12-well plate for
checking the human pMHC expression.
Culture and restimulation of human CTL. E183-91 epitope-speciﬁc human CTL,
C18-91, or E183-91 epitope-speciﬁc TCR-transduced human T cells were made as
described40,41. The E183 CTL have not been authenticated and not been tested for
mycoplasma. PBMC were freshly isolated by Ficoll-Paque PLUS (GE Healthcare
Life Sciences) according to the manufacturer’s protocol and irradiated at 30 Gy.
PBMC were resuspended in Aim-V medium with 2% human serum (Sigma-
Aldrich) at a concentration of 2 × 106 per ml. Human CTL were resuspended in the
same medium at 106 per ml. Totally, 500 μl of PBMC and 500 μl of human CTL
were pooled per well in a 24-well plate. Final concentrations of 20 Uml−1 human
recombinant IL-2, 10 ng ml−1 of IL-7, 10 ng ml−1 of IL-15 (R&D Systems) were
added to the human CTL culture. Lectin from Phaseolus vulgaris (Sigma-Aldrich)
was added to the human CTL culture at a concentration of 1.5 μg ml−1. PBMC
were collected from healthy volunteers under the protocol approved by NUS IRB.
Informed consent was obtained from all donors. GAG-A2-speciﬁc TCR-transduced
T cells were made as described27.
T-cell activation assays. One day before the T-cell activation assays, human CTL
were resuspended in Aim-V media containing 2% human serum without the
addition of extra cytokines. Human CTL were counted and resuspended at a
concentration of 106 per ml, to which the following were added: anti-CD107a
antibody (1:100), GolgiPlug Protein transport inhibitor (Brefeldin A, BD
Bioscience, 1:1000). The growth media was removed from the culture plate con-
taining CHO cells, and 200 μl of the human CTL mixture was added into each well
of the 96-well plate. Technical triplicates were set for the experiments. The plate
was incubated at 37 °C, 5% CO2 for 3 h. Surface and intracellular staining were
done according to the manufacturer’s protocol (BD Cytoﬁx/Cytoperm, BD Perm/
Wash, BD Biosciences)
Flow cytometry. Flow cytometry experiments were conducted on BD LSRFortessa
X-20 (Becton Dickinson). Cell sorting was conducted on Mo-ﬂo XDP (Beckman
Coulter, Inc.). Data analysis were performed on FlowJo (TreeStar). FACS gating
strategies are included in Supplementary Fig. 9.
IL-2 ELISA. Human CTL were co-cultured with CHO cells for 24 h and the
supernatant was collected for human IL-2 ELISA assay, which was performed
according to the manufacturer’s protocol (eBioscience).
Supported lipid bilayers. To prepare 0.2 mol% liposomes, 630 μl of 10 mgml−1
1,2-dioleoyl-sn-glycero-3-phosphocholine, 1.76 μl of 10 mgml−1 1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine-N-Cap-Biotinyl (CAP-biotin-PE), and 1.68 μl
of 5 mg ml−1 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl) iminodia-
cetic acid) succinyl] (Ni-NTA-DOGS) were mixed in eppendorf tubes. All the
lipids were from Avanti Polar Lipids, Inc. Chloroform was evaporated under N2 at
37 °C and the lipid mixture was dried in a Speedvac for 2 h. 2 ml of deoxygenized
ddH2O was then added to dissolve the lipids, which were incubated at 4 °C
overnight. The next day, the lipids were sonicated until the solution became
transparent and ﬁltered through a 0.22 μm ﬁlter. This yielded a 4 mM lipid stock
that was deoxygenized and stored at 4 °C until reconstitution. Glass 8-well chamber
LabTekII chamber slides (Fisher Scientiﬁc) were cleaned in 6 M NaOH for 2 h and
rinsed with ddH2O. The lipids were diluted 10-folds in PBS, added to clean
chamber slides and incubated for 30 min. Excess liposomes were washed away with
12 ml PBS. The bilayers were blocked with 2 mgml−1 BSA for 30 min. This was
followed by incubating with 5 μg ml−1 streptavidin for 30 min. After washing the
excess streptavidin, biotinylated MHCI, recombinant human ICAM1 Protein,
hIgG1-Fc.His Tag (Thermo Fisher Scientiﬁc) were added to the bilayers for 30 min.
After washing, the bilayers were ready to use.
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Fig. 9 Analog ampliﬁer model for the mechanism of coagonism. Nonstimulatory pMHC molecules recruit CD8-Lck into the immunological synapse.
Preconcentrated Lck further phosphorylate the ITAMs of TCR-CD3ζ which are engaged with speciﬁc antigenic pMHC. Enhanced pCD3ζ provide more
docking sites for Zap70 to be phosphorylated. Enhanced pZap70 signal ampliﬁes the downstream TCR signaling pathway including the phosphorylation of
Erk. pErk translocates into the nucleus and enhances the effector functional readouts of T-cell activation
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pLck and pZap70 imaging by TIRF microscopy. Human E183 CTL were
resuspended at 106 per ml and 100 μl of the cells was added to each well containing
the lipid bilayer and the speciﬁc pMHC monomer. The CTL were stimulated for 5
min at 37 °C, and the reaction was stopped by adding 100 μl of 8% paraf-
ormaldehyde. The cells were ﬁxed at room temperature for 12 min. The samples
were permeabilized with 0.3% Triton-X 100 for 4 min at room temperature, then
blocked with 10% normal goat serum for 1 h. To visualize pLck or pZap70, the
sample was labeled with 1:100 of anti-pSrc (Y416) (Cat# 6943 T) or anti-pZap70
(pY319) (Cat# 2717S) (Cell Signaling Technology) for 1 h at room temperature,
followed by incubation with Alexa Fluor 488F(ab’) 2 fragment of goat anti-rabbit
IgG (H+ L) at a working concentration of 5 μg ml−1 (Invitrogen). TIRF micro-
scopy was performed on an Olympus IX83 inverted microscope ﬁtted with a four-
laser TIRF module. Images were acquired using a 100×/1.49 NA oil-immersion
lens. Fluorescence excited within the 100-nm evanescent ﬁeld was recorded with a
Hamamatsu ORCA Flash 4.0 camera.
Western blotting. 105 T-REx CHO cells were seeded per well in a 24-well plate.
The T-REx CHO cell panel used was: E183 low, E183 high, GAG high, E183+
GAG, and untransfected CHO. The human E183 CTL were kept in Aim-V media
without any cytokines overnight. After overnight growth, 106 human E183 CTL
were added into each well of CHO cells, and incubated at 37 °C, 5% CO2 for 5 min
or 30 min. The mixture of CHO cells and E183 CTL were collected and lysed in
120 μl of maltoside lysis buffer. The samples were loaded in a 4–12% Bis-Tris
gradient gel (NuPAGE, Invitrogen) and transferred to a PVDF membrane
(Immobilon- FL Transfer Membrane, Merck Millipore). The membrane was then
blocked using blocking buffer (Odyssey, LI-COR) for 1 h at room temperature.
Subsequently, the membrane was probed with different primary antibodies. The
secondary antibodies used were IRDye 800CW Goat anti-Mouse IgG2b (Cat#
926–32352, LI-COR) and IRDye 680LT Goat anti-Rabbit (Cat#926-68021). The
blotting was quantiﬁed by the LI-COR Odyssey infrared imaging system.
Exclusion criteria and randomization of samples. No samples were excluded
from the analysis. No randomization was used for samples.
Statistical information and data analysis. Two-tailed Student t test analysis was
performed using GraphPad Prism 7. The data meet the assumptions of the tests.
Variance is similar between the compared groups.
Data availability. The datasets generated during and/or analyzed during the
current study are available from the corresponding author on request.
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